目的 探討黃梔花口服液聯(lián)合阿莫西林克拉維酸鉀干混懸劑醫(yī)治小兒急性上呼吸道感染的臨床效果。方法 選取2017年1月-2018年1月在南陽市中心醫(yī)院就診的150例急性上呼吸道感染患兒，根據(jù)用藥的差別分為治療組、對照組（每組75名）。對照組患兒口服阿莫西林克拉維酸鉀干混懸劑，7~12歲兒童1袋半/次，2~7歲1袋/次，9個(gè)月~2歲半袋/次，1次/12 h；治療組患兒在對照組基礎(chǔ)上口服黃梔花口服液，2~3歲5 mL/次，4~6歲10 mL/次，7~10歲15 mL/次，≥ 11歲20 mL/次，3次/d。兩組患兒均經(jīng)7 d治療。觀察并比較兩組臨床效果、癥狀消失時(shí)間及血清炎癥因子改善情況。結(jié)果 經(jīng)治療，對照組有效率為82.67%，顯著低于治療組（97.33%，P<0.05）。經(jīng)治療，在咳嗽、發(fā)熱、咽部腫痛及咽部充血等癥狀消失時(shí)間上治療組短于對照組（P<0.05）。經(jīng)治療，兩組患者血清超敏C反應(yīng)蛋白（hs-CRP）、淀粉樣蛋白A（SAA）、白細(xì)胞介素-4（IL-4）、嗜酸性細(xì)胞陽離子蛋白（EOS）、降鈣素原（PCT）水平均下降（P<0.05）；且治療組更顯著（P<0.05）。結(jié)論 小兒急性上呼吸道感染采用阿莫西林克拉維酸鉀同黃梔花口服液共同治療能夠明顯改善患兒臨床癥狀，促使機(jī)體炎癥消退，有著很好應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Huangzhihua Oral Liquid combined with amoxicillin clavulanate potassium in treatment of acute upper respiratory tract infection in children. Methods Children (150 cases) with acute upper respiratory tract infection in Nanyang Central Hospital from January 2017 to January 2018 were divided into control (75 cases) and treatment (75 cases) groups bases on different treatments. Children in the control group were po administered with Amoxicillin and Clavulanate Potassium for Suspension, 1.5 bag/time for 7-12 years old children, 1 bag/time for 2-7 years old children, 0.5 bag/time for 9 months-2 years old children, once every 12 h. Children in the treatment group were po administered with Huangzhihua Oral Liquid on the basis of the control group, 5 mL/time for 2-3 years old children, 10 mL/time for 4-6 years old children, 15 mL/time for 7-10 years old children, 20 mL/time for more than 11 years old children, three times daily. Children in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the serum levels of hs-CRP, SAA, IL-4, EOS and PCT in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.67%, which was significantly lower than 97.33% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the disappearance time of cough, fever, sore throat and congestion of the pharynx in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the serum levels of hs-CRP, SAA, IL-4, EOS and PCT in two groups were significantly decreased (P<0.05), and these serum factor levels in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Huangzhihua Oral Liquid combined with amoxicillin clavulanate potassium in treatment of acute upper respiratory tract infection in children can significantly improve the clinical symptoms and promote inflammation to subside, which has a certain clinical application value.

R974

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（201503114）